Patents

US 9040591 B2: Methods and compositions comprising at least one α3 βA4 nAChR antagonist or pharmaceutically acceptable salt thereof

Granted
2015-05-26
Filed
2012-07-19 application 13553453
Type
Utility · 12 claims
Elsewhere
Google Patents ↗ · USPTO patent document ↗ · USPTO Patent Center record ↗

Abstract

The present invention is directed to methods and formulations for treating, modifying, and/or managing gastrointestinal secretion, and intestinal conditions that cause the same. Methods of using at least one α3 β4 nAChR antagonist and formulations comprising at least one α3 β4 nAChR antagonist, or pharmaceutically acceptable salt thereof, are included.

Source: PVGPATDIS, file of 2026-04-10 (ipg150526.xml).

Assignees

AssigneeTypePlaceAlso on furp.orgSource
AGI Therapeutics Public Limited Company 1 patentsForeign company or organizationDublin, IEPVGPATDIS, file of 2026-04-10

Inventors

InventorPlacePatentsPerson pageSource
John DevaneRoscommon, IE16PVGPATDIS, file of 2026-04-10

CPC categories

SubclassCategoryFirst groupSource
A61KPreparations for medical, dental or toiletry purposesA61K45/06PVGPATDIS, file of 2026-04-10
A61PSpecific therapeutic activity of chemical compounds or medicinal preparationsA61P1/00PVGPATDIS, file of 2026-04-10

Cooperative Patent Classification, as currently assigned (one row per subclass).

Assignments and security interests

RecordedWhatFromToReel/frameSource
2023-10-06Release of security interest
Release of security interest
CITIBANK, N.A. signed 2023-10-06HORIZON THERAPEUTICS IRELAND DAC (SUCCESSOR IN INTEREST TO HORIZON PHARMA SERVICES LIMITED) DUBLIN 2
HORIZON THERAPEUTICS IRELAND DAC (FKA HORIZON PHARMA IRELAND LIMITED) DUBLIN 2
HORIZON THERAPEUTICS USA, INC. (FKA HORIZON PHARMA USA, INC.) DEERFIELD, IL
HZNP LIMITED DUBLIN 2
65153/953PASDL, file of 2026-10-15
2018-08-14Assignment
Assignment of assignor's interest
HORIZON PHARMA SERVICES LIMITED signed 2018-08-14HORIZON PHARMA IRELAND LIMITED DUBLIN 446803/950ECORSEXC, file of 2026-09-25
2015-08-12Name change
Change of name
AGI THERAPEUTICS LIMITED signed 2014-10-03HORIZON PHARMA SERVICES LIMITED DUBLIN36309/553ECORSEXC, file of 2026-09-25
2015-05-07Security interest Security interest
Security interest
HORIZON PHARMA SERVICES LIMITED (FORMERLY AGI THERAPEUTICS LIMITED) signed 2015-05-07CITIBANK, N.A. NEW YORK, NY35590/889ECORSEXC, file of 2026-09-25

Documents recorded with the USPTO Assignment Recordation Branch that list this patent. A security interest is a lender’s claim on the patent as collateral; a release ends it.

USPTO bulk data: PatentsView granted patents, disambiguated (PVGPATDIS) for patents, assignees, inventors, places and CPC categories; the USPTO Patent Assignment Dataset (ECORSEXC) for assignments and security interests. Patents filed in the last 20 years. No claims or full text. Links to other records are by name (and state): EXACT means the identical full name and state; FUZZY means a looser name match, with the confidence shown.